Pegzilarginase not checked

Immedica Pharma AB · AEB1102

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
None yet
 
Trials
0 active
8 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated”In the company’s words, NCT03921541 on ClinicalTrials.gov
Tested for
Arginase I Deficiency (3 trials), Hyperargininemia (3 trials), Arginase 1 Deficiency, Small-cell Lung Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Advanced Cancers
Main trialPhase 3
“CAEB1102-300A is a multi-center randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pegzilarginase in patients with ARG1-D. This study will consist of a screening period; a randomized, double-blind treatment period; a long-term extension; and a follow up visit for final safety assessments.”In the company’s words, NCT03921541 on ClinicalTrials.gov
Other names
AEB1102 · Co-ArgI-PEG · Loargys

Other drugs for Arginase I Deficiency

All 1 drugs for Arginase I Deficiency

Coming up0

No dates coming up.

Changes1

Last 90 days

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Completed 1 Feb 2023 Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
Phase 3Completed 17 Jun 2025 Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency
Phase 2Completed 15 Dec 2022 A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
Phase 1/2Completed 28 Feb 2019 A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency
Phase 1/2Terminated 11 Jun 2020 Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Phase 1Completed 1 Nov 2017 A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Phase 1Completed 28 May 2019 A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Phase 3Ended not given A Phase 3 Open-Label Study of Safety, Pharmacokinetics and Activity of Weekly Subcutaneous Pegzilarginase in Subjects <24 months old with Arginase 1 Deficiency
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pegzilarginase

Following is part of Solo: you see every change to Pegzilarginase the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in